Prostaglandin-E1-Alprostadil-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEProstaglandinE1Cat.No.:HY-B0131CASNo.:745-65-3Synonyms:Alprostadil;PGE1分⼦式:C₂₀H₃₄O₅分⼦量:354.48作⽤靶点:ProstaglandinReceptor;EndogenousMetabolite作⽤通路:GPCR/GProtein;MetabolicEnzyme/Protease储存⽅式:4°C,storedundernitrogen*该产品在溶液状态不稳定，建议您现⽤现配，即刻使⽤。溶解性数据体外实验Ethanol:100mg/mL(282.10mM;Needultrasonic)DMSO:100mg/mL(282.10mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制备储备液1mM2.8210mL14.1052mL28.2103mL5mM0.5642mL2.8210mL5.6421mL10mM0.2821mL1.4105mL2.8210mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现⽤现配，即刻使⽤.体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(7.05mM);Clearsolution2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemESolubility:≥2.5mg/mL(7.05mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(7.05mM);Clearsolution4.请依序添加每种溶剂：10%EtOH>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(7.05mM);Clearsolution5.请依序添加每种溶剂：10%EtOH>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(7.05mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性ProstaglandinE1(Alprostadil)⼀种前列腺素受体配体，对⼩⿏EP3、EP4、EP2、IP和EP1的Ki值分别为1.1nM、2.1nM、10nM、33nM和36nM。ProstaglandinE1诱导⾎管舒张并抑制⾎⼩板聚集。ProstaglandinE1可作为⾎管扩张剂⽤于外周⾎管疾病的研究。IC50&TargetHumanEndogenousMetabolite体外研究ProstaglandinE1(1nM-10μM;48h)concentration-dependentlyreducesHUVECsproliferation(upto100%inhibition)inthepresenceofVEGF(20ng/mL),withanIC50of400nM[2].ProstaglandinE1(0.01-10μM;6h)inhibitsVEGF-inducedHUVECsmigrationinaconcentrationdependentmanner,withanIC50of500nM[2].ProstaglandinE1(1-5μM;12-18h)inhibitsinvitroangiogenesis[2].ProstaglandinE1(0.01-10μM;20min)increasesintracellularcAMPlevelsinHUVECs[2].体内研究ProstaglandinE1(20ng/animal/day;s.c.for4days)significantlyinhibitstheFGF-inducedangiogenesisinmice[2].AnimalModel:C57/bl6femalemice(6-8weeks)wereinjectedwithMatrigelsupplementedwithaFGFandheparin[2]Dosage:20ng/day/animalAdministration:Minipumpplacedsubcutaneouslyfor4daysResult:Visiblyreducedtheneovascularizationprocess.户使⽤本产品发表的科研⽂献•ActaPharmSinB.12January2022.•JControlRelease.2019May6;304:233-241.•NanoRes.11,6086-6101(2018).•OxidMedCellLongev.17Jan2022.•IntJMolSci.2022,23(20),12345.2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemESeemorecustomervalidationsonwww.MedChemEREFERENCES[1].KiriyamaM,et,al.LigandbindingspecificitiesoftheeighttypesandsubtypesofthemouseprostanoidreceptorsexpressedinChinesehamsterovarycells.BrJPharmacol.1997Sep;122(2):217-24.[2].CattaneoMG,et,al.AlprostadilsuppressesangiogenesisinvitroandinvivointhemurineMatrigelplugassay.BrJPharmacol.2003Jan;138(2):377-85.[3].HauckEW,et,al.ProstaglandinE1long-termself-injectionprogrammefortreatmentoferectiledysfunction--afollow-upofatleast5years.Andrologia.1999;31Suppl1:99-103.McePdfHeightCaution:Producthasnotbeen